The IL-2 pathway, which was the first immunotherapy approved for cancer treatment nearly 30 years ago by the U.S. Food and Drug Administration (FDA) 77, plays a crucial role in counteracting the dysregulated immune system by targeting regulatory T cells and enhancing antitumor responses through effector, memory, and natural killer cells 78,79. Here, IL2 is linked to cancer.